Western Eye Hospital, Imperial College Healthcare NHS Trust, London, UK.
Imperial College London, London, UK.
Eur J Ophthalmol. 2021 Sep;31(5):2481-2487. doi: 10.1177/1120672120963455. Epub 2020 Nov 2.
To describe real world data in patients affected by myopic choroidal neovascularization (CNV) treated with anti-vascular endothelial growth factors (VEGFs) and to compare our results with previous studies and clinical trials.
This retrospective monocentric cohort study analyzed 96 eyes of 96 myopic-CNV patients treated with an anti-VEGF pro-re-nata regimen over a 3-year-long follow up period. Aflibercept and Ranibizumab were considered as first-line agents whereas Bevacizumab was reserved on a compassionate basis in patients outside the criteria for treatment. All patients underwent a best-corrected visual acuity (BCVA) recording at each follow up visit.
Our data showed that all three molecules produced significant improvements in BCVA at year 1, with no significant differences between the three drugs. Moreover, during the second year of treatment, Ranibizumab and Bevacizumab showed a significant improvement in the visual function. However, at year 3 of treatment, the data available indicated the BCVA improvement was not significant with Ranibizumab and Bevacizumab. In addition, no significant difference in the average number of injections between the three groups was detected over the follow up period. No serious adverse events were recorded, but five minor adverse events documented.
Our study correlates with previous studies showing significant BCVA gains with the use of these molecules. Similarly, all three molecules seem to provide a similar duration of effects as previous studies have shown, with a low ocular adverse event rate.
描述接受抗血管内皮生长因子（VEGF）治疗的近视性脉络膜新生血管（CNV）患者的真实世界数据，并将我们的结果与之前的研究和临床试验进行比较。
这是一项回顾性单中心队列研究，分析了 96 例接受抗 VEGF 序贯治疗的近视性 CNV 患者的 96 只眼，随访时间为 3 年。阿柏西普和雷珠单抗被视为一线药物，而贝伐单抗则在不符合治疗标准的患者中基于同情使用。所有患者在每次随访时均进行最佳矫正视力（BCVA）记录。
我们的数据显示，所有三种药物在第 1 年均显著提高了 BCVA，且三种药物之间无显著差异。此外，在治疗的第 2 年，雷珠单抗和贝伐单抗的视力功能有显著改善。然而，在治疗的第 3 年，可用数据表明雷珠单抗和贝伐单抗的 BCVA 改善不显著。此外，在随访期间，三组之间的平均注射次数无显著差异。未记录到严重不良事件，但有 5 例轻微不良事件。
我们的研究与之前的研究相吻合，表明这些药物的使用可显著提高 BCVA。同样，正如之前的研究所示，所有三种药物似乎都提供了相似的疗效持续时间，且眼部不良事件发生率较低。
